培米替尼全网公布的2025年最新价格

Pemetinib is a targeted drug used to treat cholangiocarcinoma, especially for patients with FGFR2 gene fusion or rearrangement. This article will conduct a detailed analysis of the latest price of pemetinib in 2025, global marketing status, and drug preparation to help patients better understand the economics and usage of the drug.

The latest price of pemetinib in 2025 published on the entire website

The original drug has been launched in China. Its price varies depending on the specifications and is for reference only.

Original drug price

The original drug of pemetinib is produced by Incyte Biosciences Distribution B.V., and the price is relatively high. The price of a box of 9mg*14 pills is about US$5,781, and the price of a box of 4.5mg*14 pills is about US$3,400.

Price of generic drugs

The generic version of pemetinib produced by Lucius in Laos is 4.5mg*14 tablets, and the price of a box is about US$60. The price of generic drugs is relatively low, but patients should pay attention to the quality and efficacy of the drug when choosing generic drugs.

There is a large price difference between the original drug and generic drug of pemetinib, and patients can choose according to their own economic situation and treatment needs.

Global marketing status of pemetinib

Pemetinib has been launched in many countries and regions, including the United States, Europe, China, etc. The drug was approved by the US FDA in April 2020 for the treatment of patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement.

US marketing status

Pemetinib was approved by the US FDA in April 2020 for the treatment of patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement. This approval marks the official entry of pemetinib into the U.S. market, providing American patients with a new treatment option.

Marketing status in China

Pemetinib was conditionally approved for marketing by the China National Medical Products Administration (NMPA) on March 29, 2022, for the treatment of patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement. This approval marks the official entry of pemetinib into the Chinese market, providing Chinese patients with a new treatment option.

The launch of pemetinib in many countries and regions around the world provides new treatment options for patients with cholangiocarcinoma. Patients can choose appropriate drugs according to their own conditions.

Preparation for the administration of pemetinib

The preparation for the administration of pemetinib needs to be adjusted according to the specific situation of the patient.

Patient Selection

Before using pemetinib tablets to treat patients with locally advanced or metastatic cholangiocarcinoma, validated detection methods should be used to determine the presence of FGFR2 fusion or rearrangement in the patient. Patients who are diagnosed as carrying FGFR2 fusion or rearrangement through genetic testing in the hospital or laboratory can receive this product.

Recommended dose

The recommended dose of pemetinib is 13.5 mg, administered orally once daily for 14 consecutive days, followed by 7 days of discontinuation, and every 21 days constitutes a treatment cycle. Treatment is continued until disease progression or intolerable toxicity occurs.

Dose adjustment

If the dose needs to be reduced due to adverse reactions, please refer to the recommended dose reduction plan in Table 1. The first taper is 9 mg once a day during the first 14 days of every 21-day cycle; the second taper is 4.5 mg once a day during the first 14 days of every 21-day cycle. If reduction to 4.5 mg once daily is still not tolerated, discontinue treatment permanently.

Pemetinib medication preparation needs to be adjusted according to the patient's specific situation, and patients should be treated according to the doctor's recommendations.